Commercial Aquaculture Vaccines Market

Commercial Aquaculture Vaccines Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The commercial aquaculture vaccines market size was estimated to be US$ 272.91 Million in 2022.

The commercial aquaculture vaccines market is expected grow at a CAGR of 7.4% between 2023 to 2032.

The global commercial aquaculture vaccines market is being driven by the rising prevalence of aquatic diseases, such as bacterial infections and parasitic infections and growing investment in the aquaculture industry, both from governments and private organizations, is leading to increased production of fish and seafood.

The North American market for commercial aquaculture vaccines is driven by the presence of large aquaculture industries in the US and Canada, particularly for species such as salmon, trout, and catfish.

The major growth strategies adopted by these companies are investing in marketing and branding to increase awareness of their products and build brand loyalty among customers.

Based on species, the salmon segment is one of the largest segments in the market due to the high demand for farmed salmon and the prevalence of diseases that affect the species.

AB Vista, AniCon Labor GmbH, Benchmark Holdings Plc, Hipra, Merck & Co., Inc., Nisseiken Co., Ltd., Novartis International AG, Pfizer Inc., PHARMAQ AS, Tecnovax SA, Vaxxinova GmbH, Vetanco, Virbac, Zoetis Inc., Zydus Animal Health KP among others, are the leading players in this market.